Danielle Talbert
Physician Assistant · Woodlands, TXNPI 1497000590
Payments from drug & device makers
Across 266 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$971
- Regeneron Healthcare Solutions, Inc.$820
- AstraZeneca$601
- Sanofi$563
- Grifols USA, LLC$375
- Blueprint Medicines Corporation$314
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,71396%
- Education$2294%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 44 | $971 |
| Regeneron Healthcare Solutions, Inc. | 30 | $820 |
| AstraZeneca | 29 | $601 |
| Sanofi | 22 | $563 |
| Grifols USA, LLC | 26 | $375 |
| Blueprint Medicines Corporation | 8 | $314 |
| Amgen | 16 | $271 |
| Genentech USA, Inc. | 12 | $248 |
| CSL Behring | 10 | $214 |
| Novartis | 10 | $184 |
| LEO Pharma Inc. | 11 | $183 |
| Lilly USA, LLC | 7 | $157 |
| Pharming Healthcare, Inc. | 7 | $154 |
| Kaleo, Inc. | 5 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $104 |
| Tersera Therapeutics LLC | 5 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Alk-abello, Inc | 4 | $76 |
| Optinose US, Inc. | 3 | $69 |
| Incyte Corporation | 3 | $62 |
| Octapharma USA, Inc. | 1 | $55 |
| Ossur Americas, Inc. | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Phadia US Inc. | 1 | $27 |
| GC Biopharma USA, Inc. | 1 | $26 |
| AbbVie | 1 | $24 |
| Biocryst US Sales Co., LLC | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
How this compares
$5,942 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $14,789 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,464 |
| Arnuity ElliptaFluticasone Furoate | 18 | $3,915 |
| Epinephrine | 12 | $2,036 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $1,966 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,466 |
| Ipratropium Bromide | 24 | $891 |
| Montelukast Sodium | 46 | $236 |
| Azithromycin | 17 | $183 |
| Hydroxyzine Hcl | 14 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $971 | $24,16853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Woodlands
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.